Literature DB >> 28490538

Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance.

Christine Levesque1, Peter S Nelson1.   

Abstract

Reciprocal signaling between prostate stroma and its epithelium are fundamental to organ development and homeostasis. Similarly, interactions between tumor cells and stromal constituents are central to key aspects of carcinogenesis and malignancy growth involving tumor cell invasion, dissemination, and growth in distant sites. The prostate stroma is complex with several distinct resident cell types, infiltrating nonresident cell types and an amalgam of structural matrix factors, matricellular proteins, metabolites, growth factors, and cytokines. Of importance, the stroma is dynamic with changes in composition as a cause or consequence of intrinsic and extrinsic factors. In the context of epithelial neoplasia, the prostate stroma undergoes phenotypic changes with a loss of well-differentiated smooth muscle cell population and the expansion of cancer-associated fibroblast populations. This reactive stroma further coevolves with tumor progression. Recent studies show the role of tumor microenvironment components in therapy resistance and highlight the importance of a thorough knowledge of cross talk between tumor cells and microenvironment niches to develop new therapeutic strategies.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 28490538      PMCID: PMC5681439          DOI: 10.1101/cshperspect.a030510

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  135 in total

Review 1.  Tissue cells feel and respond to the stiffness of their substrate.

Authors:  Dennis E Discher; Paul Janmey; Yu-Li Wang
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

2.  A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.

Authors:  Benjamin Beck; Gregory Driessens; Steven Goossens; Khalil Kass Youssef; Anna Kuchnio; Amélie Caauwe; Panagiota A Sotiropoulou; Sonja Loges; Gaelle Lapouge; Aurélie Candi; Guilhem Mascre; Benjamin Drogat; Sophie Dekoninck; Jody J Haigh; Peter Carmeliet; Cédric Blanpain
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

3.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 4.  Drug resistance and the solid tumor microenvironment.

Authors:  Olivier Trédan; Carlos M Galmarini; Krupa Patel; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

5.  Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts.

Authors:  Elisabeth M Zeisberg; Scott Potenta; Liang Xie; Michael Zeisberg; Raghu Kalluri
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

6.  Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer.

Authors:  Chris Parker; Michael Milosevic; Ants Toi; Joan Sweet; Tony Panzarella; Rob Bristow; Charles Catton; Pamela Catton; Juanita Crook; Mary Gospodarowicz; Michael McLean; Padraig Warde; Richard P Hill
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

7.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

Authors:  Tetsuichiro Inai; Michael Mancuso; Hiroya Hashizume; Fabienne Baffert; Amy Haskell; Peter Baluk; Dana D Hu-Lowe; David R Shalinsky; Gavin Thurston; George D Yancopoulos; Donald M McDonald
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

8.  Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.

Authors:  Kelly L Mueller; Julie M Madden; Gina L Zoratti; Charlotte Kuperwasser; Karin List; Julie L Boerner
Journal:  Breast Cancer Res       Date:  2012-07-12       Impact factor: 6.466

Review 9.  Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors.

Authors:  Jason M Butler; Hideki Kobayashi; Shahin Rafii
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

10.  Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors.

Authors:  Ting Zhang; Yuk Wai Lee; Yun Feng Rui; Tin Yan Cheng; Xiao Hua Jiang; Gang Li
Journal:  Stem Cell Res Ther       Date:  2013-06-13       Impact factor: 6.832

View more
  17 in total

Review 1.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

2.  Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.

Authors:  Peggi M Angel; Laura Spruill; Melanie Jefferson; Jennifer R Bethard; Lauren E Ball; Chanita Hughes-Halbert; Richard R Drake
Journal:  Prostate       Date:  2020-07-20       Impact factor: 4.104

3.  Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes.

Authors:  Christopher M Heaphy; Corinne E Joshu; John R Barber; Christine Davis; Reza Zarinshenas; Angelo M De Marzo; Tamara L Lotan; Karen S Sfanos; Alan K Meeker; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-08       Impact factor: 4.254

Review 4.  Prostate zones and cancer: lost in transition?

Authors:  Amin Ali; Alexander Du Feu; Pedro Oliveira; Ananya Choudhury; Robert G Bristow; Esther Baena
Journal:  Nat Rev Urol       Date:  2021-10-19       Impact factor: 14.432

5.  Prostate epithelial-specific expression of activated PI3K drives stromal collagen production and accumulation.

Authors:  Kyle A Wegner; Brett R Mueller; Christopher J Unterberger; Enrique J Avila; Hannah Ruetten; Anne E Turco; Steven R Oakes; Nicholas M Girardi; Richard B Halberg; Steven M Swanson; Paul C Marker; Chad M Vezina
Journal:  J Pathol       Date:  2019-11-28       Impact factor: 7.996

Review 6.  Aging of the progenitor cells that initiate prostate cancer.

Authors:  Jack Freeland; Preston D Crowell; Jenna M Giafaglione; Paul C Boutros; Andrew S Goldstein
Journal:  Cancer Lett       Date:  2021-05-28       Impact factor: 8.679

7.  Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression.

Authors:  Simon W Hayward; Gustavo Ayala; Alexander R A Anderson; Ziv Frankenstein; David Basanta; Omar E Franco; Yan Gao; Rodrigo A Javier; Douglas W Strand; MinJae Lee
Journal:  Nat Ecol Evol       Date:  2020-05-11       Impact factor: 19.100

8.  Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma.

Authors:  Maria K Andersen; Kjersti Rise; Guro F Giskeødegård; Elin Richardsen; Helena Bertilsson; Øystein Størkersen; Tone F Bathen; Morten Rye; May-Britt Tessem
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

Review 9.  Direct Intercellular Communications and Cancer: A Snapshot of the Biological Roles of Connexins in Prostate Cancer.

Authors:  Catalina Asencio-Barría; Norah Defamie; Juan C Sáez; Marc Mesnil; Alejandro S Godoy
Journal:  Cancers (Basel)       Date:  2019-09-14       Impact factor: 6.639

Review 10.  Cellular rewiring in lethal prostate cancer: the architect of drug resistance.

Authors:  Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2020-03-16       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.